Award
National Heart, Lung, and Blood Institute 5R35HL161249-05
New and Disruptive Therapeutic Approaches to Target Fundamental Molecular Mechanisms Underlying Atrial Fibrillation
Recipient
University of Chicago, Chicago, IL, United States
Award Amount
$1,208,768.00
Ceiling
$1,208,768.00
Awarded
May 26, 2026
Identifier
5R35HL161249-05
Research project funded by NHLBI to develop gene therapy approaches targeting molecular mechanisms underlying atrial fibrillation to improve treatment efficacy and prevent disease progression.
Description
This project aims to study the role of three major molecular mechanisms—autonomic nervous system remodeling, NLRP3 induced fibrosis, and derailed proteostasis—in the genesis of persistent atrial fibrillation (AF) using novel biological agents (genes) to target these mechanisms. Success could lead to therapeutic potential in managing this arrhythmia.